|
ATP6V1H expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.444020E-03 |
| Normal-vs-Stage3 |
1.66533453693773E-15 |
| Normal-vs-Stage4 |
1.65778502037028E-12 |
| Stage1-vs-Stage2 |
6.536300E-03 |
| Stage1-vs-Stage3 |
4.565200E-01 |
| Stage1-vs-Stage4 |
7.628200E-02 |
| Stage2-vs-Stage3 |
3.198300E-03 |
| Stage2-vs-Stage4 |
5.150900E-04 |
| Stage3-vs-Stage4 |
2.674400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
9.50429999999614E-05 |
| Normal-vs-Asian |
6.71718236588958E-12 |
| Caucasian-vs-AfricanAmerican |
1.942960E-01 |
| Caucasian-vs-Asian |
8.202200E-01 |
| AfricanAmerican-vs-Asian |
1.941200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.77635683940025E-15 |
| Normal-vs-Female |
1.62536650805123E-12 |
| Male-vs-Female |
1.917590E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(41-60Yrs) |
5.32907051820075E-15 |
| Normal-vs-Age(61-80Yrs) |
2.06200000407719E-08 |
| Normal-vs-Age(81-100Yrs) |
4.43850000000356E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.740600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.352100E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.592400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.018780E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.297000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.149400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.295700E-02 |
| Classical-VS-Follicular |
1.55319999999293E-05 |
| Classical-VS-Other |
7.227000E-01 |
| Classical-VS-Normal |
1.62470037423645E-12 |
| Tall-VS-Follicular |
7.96729999974488E-07 |
| Tall-VS-Other |
6.271200E-01 |
| Tall-VS-Normal |
1.62969637784727E-12 |
| Follicular-VS-Other |
1.000580E-01 |
| Follicular-VS-Normal |
2.991600E-04 |
| Other-VS-Normal |
6.4466999999957E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.69473373907203E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
6.1839000000008E-05 |
|
|
